Mona Wahba

1.8k total citations · 1 hit paper
34 papers, 598 citations indexed

About

Mona Wahba is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mona Wahba has authored 34 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mona Wahba's work include Colorectal Cancer Treatments and Studies (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Treatment and Pharmacology (7 papers). Mona Wahba is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Treatment and Pharmacology (7 papers). Mona Wahba collaborates with scholars based in United Kingdom, United States and Australia. Mona Wahba's co-authors include Oliver Sartor, Sten Nilsson, Nicholas J. Vogelzang, David Bottomley, John Logue, Svein Inge Helle, Joe M. O’Sullivan, Anne-Kirsti Aksnes, Fang Fang and Dag Clement Johannessen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Mona Wahba

32 papers receiving 584 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

2014 290 citations Peter Hoskin, Oliver Sartor et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mona Wahba United Kingdom	10	313	246	210	120	92	34	598
Z. Win United Kingdom	11	332 1.1×	150 0.6×	105 0.5×	150 1.3×	157 1.7×	16	818
Pietro Castellan Italy	15	439 1.4×	105 0.4×	98 0.5×	189 1.6×	54 0.6×	37	723
F. Innocenti Italy	10	367 1.2×	198 0.8×	211 1.0×	61 0.5×	28 0.3×	25	676
Maria Laura Canale Italy	15	209 0.7×	116 0.5×	204 1.0×	122 1.0×	141 1.5×	77	895
Pilar Auñón Spain	12	153 0.5×	124 0.5×	179 0.9×	48 0.4×	20 0.2×	40	546
Mathieu Gauthé France	15	374 1.2×	167 0.7×	151 0.7×	125 1.0×	35 0.4×	60	569
Chad A. Reichard United States	15	493 1.6×	50 0.2×	93 0.4×	114 0.9×	159 1.7×	42	707
Lucia Kwak United States	17	255 0.8×	55 0.2×	106 0.5×	188 1.6×	63 0.7×	40	636
Neşe Torun Türkiye	11	117 0.4×	125 0.5×	33 0.2×	94 0.8×	34 0.4×	43	329
Xia Lu China	11	91 0.3×	150 0.6×	67 0.3×	65 0.5×	23 0.3×	38	471

Countries citing papers authored by Mona Wahba

Since Specialization

Citations

This map shows the geographic impact of Mona Wahba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Wahba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Wahba more than expected).

Fields of papers citing papers by Mona Wahba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Wahba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Wahba. The network helps show where Mona Wahba may publish in the future.

Co-authorship network of co-authors of Mona Wahba

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Wahba. A scholar is included among the top collaborators of Mona Wahba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Wahba. Mona Wahba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lama, Daniel, Mona Wahba, Abubakr Imam, et al.. (2025). SAME-DAY DISCHARGE AFTER ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY: A MULTI-INSTITUTIONAL ANALYSIS. Urologic Oncology Seminars and Original Investigations. 43(3). 73–74. 1 indexed citations

De, Parijat, Andrew Frankel, Debasish Banerjee, et al.. (2025). Finerenone in the management of diabetes kidney disease. BMC Nephrology. 26(1). 63–63. 3 indexed citations

Desai, Anant, Lesley A. Inker, Irene de Lourdes Noronha, et al.. (2024). WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS). Kidney International Reports. 9(4). S550–S551.

Zac‐Varghese, Sagen, Patrick B. Mark, Steve Baín, et al.. (2024). Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024. BMC Nephrology. 25(1). 216–216. 8 indexed citations

Barratt, Jonathan, Lesley A. Inker, Irene L. Noronha, et al.. (2023). #4321 ACTION3 PHASE 3 STUDY: EVALUATING A NOVEL THERAPEUTIC STRATEGY OF A CCR2 INHIBITOR (DMX-200) WITH ANGIOTENSIN RECEPTOR BLOCKADE IN FSGS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations

Williams, Jennifer, Steve Baín, Indranil Dasgupta, et al.. (2023). Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis. Kidney International Reports. 8(4). 700–714. 9 indexed citations

Banerjee, Debasish, Peter Winocour, Tahseen A Chowdhury, et al.. (2022). Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrology. 23(1). 9–9. 46 indexed citations

Banerjee, Debasish, Peter Winocour, Tahseen A Chowdhury, et al.. (2022). Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney International Reports. 7(4). 681–687. 14 indexed citations

Makanjuola, David, et al.. (2021). Fludrocortisone Is an Effective Treatment for Hyperkalaemic Metabolic Acidosis in Kidney Transplant Recipients on Tacrolimus: A Case Series. The Nephron journals/Nephron journals. 146(2). 190–196. 5 indexed citations

10.

Dasgupta, Indranil, Debasish Banerjee, Tahseen A Chowdhury, et al.. (2017). Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease. British Journal of Diabetes. 17(4). 160–164. 6 indexed citations

11.

Tabernero, Josep, Atsushi Ohtsu, Takayuki Yoshino, et al.. (2016). PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment. Annals of Oncology. 27. ii111–ii111. 3 indexed citations

12.

Falcone, Alfredo, Atsushi Ohtsu, E. Van Cutsem, et al.. (2016). Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102). Annals of Oncology. 27. vi183–vi183. 1 indexed citations

13.

Mayer, Robert J., Atsushi Ohtsu, Takayuki Yoshino, et al.. (2016). Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial.. Journal of Clinical Oncology. 34(15_suppl). 3547–3547. 4 indexed citations

14.

Mayer, Robert J., Eric Van Cutsem, Takayuki Yoshino, et al.. (2016). Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). e15021–e15021. 6 indexed citations

15.

Ohtsu, Atsushi, Takayuki Yoshino, Mona Wahba, et al.. (2015). Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. Journal of Clinical Oncology. 33(15_suppl). 3564–3564. 6 indexed citations

16.

Shinozaki, Eiji, Stéphanie Laurent, Cristina Grávalos, et al.. (2015). 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). European Journal of Cancer. 51. S383–S384. 5 indexed citations

17.

Hoskin, Peter, Oliver Sartor, Joe M. O’Sullivan, et al.. (2014). Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology. 15(12). 1397–1406. 290 indexed citations breakdown →

18.

Michalski, Jeff M., Chris Parker, Oliver Sartor, et al.. (2014). Impact of Prior Docetaxel, Extent of Disease (EOD), and Prior Bisphosphonates (Bp) on Hematologic (Heme) Safety of Radium-223 Dichloride (Ra-223) From ALSYMPCA. International Journal of Radiation Oncology*Biology*Physics. 90(1). S441–S442. 4 indexed citations

19.

Ekman, Evan F., et al.. (2006). Analgesic Efficacy of Perioperative Celecoxib in Ambulatory Arthroscopic Knee Surgery: A Double‐Blind, Placebo‐Controlled Study. Arthroscopy The Journal of Arthroscopic and Related Surgery. 22(6). 635–642. 61 indexed citations

20.

Raza, Syed Ali, Aamer Chughtai, Mona Wahba, et al.. (2003). Multislice CT Angiography in Renal Artery Stent Evaluation: Prospective Comparison with Intra-Arterial Digital Subtraction Angiography. CardioVascular and Interventional Radiology. 27(1). 9–15. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact